AQ4N: a new approach to hypoxia-activated cancer chemotherapy
2000
AQ4N: A New Approach to Cancer Treatment
publication
Evidence: moderate
Author Information
Author(s): Patterson L H, McKeown S R
Primary Institution: Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University of London
Hypothesis
AQ4N enhances the anti-tumour effects of radiation and chemotherapy.
Conclusion
AQ4N can improve cancer treatment by enhancing the effects of radiation and chemotherapy while minimizing normal tissue toxicity.
Supporting Evidence
- AQ4N enhances the anti-tumour effects of radiation and chemotherapeutic agents.
- AQ4N has a dose-modifying factor of approximately 2.0.
- AQ4N is a bioreductive prodrug that binds non-covalently to DNA.
- AQ4N is different from previously identified bioreductive drugs.
- AQ4N is the only bioreductive prodrug topoisomerase II inhibitor to enter clinical trials.
Takeaway
AQ4N is a special medicine that helps make cancer treatments work better without hurting healthy parts of the body.
Methodology
Preclinical studies were conducted to evaluate the effects of AQ4N in enhancing anti-tumour activity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website